Each row is an authorised trial looking for participants. The plain-language title is written by our editorial team, and underneath it you can see the original registry title — so you can check for yourself that we did not change the meaning. We cannot tell you whether you are eligible, and we do not publish the hospital name: the international registry does not carry it, and a wrong name would send you to a room where nobody expects you. For the centre and the team's contact details, open the official record.
Trials recruiting now
Every title below has been rewritten in plain language by our editorial team, with the original underneath.
Trials testing a treatment · 4 studies
Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.
Recurrent platinum-sensitive ovarian cancer: a new maintenance treatment compared with standard care
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
For: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
4 centres: Spitalul Clinic Filantropia, București · Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca · S.C. Centrul de Oncologie Sf. Nectarie SRL, Craiova · and 1 more
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Platinum-resistant and platinum-sensitive ovarian cancer: a new medicine tested in three parts
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed during or within six months of platinum-based chemotherapy. Parts B and C enroll participants with platinum-sensitive cancer, whose disease responded and remained controlled for at least six months after completing platinum treatment. The researchers want to find out if Sofe-M works better than the standard treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.
3 centres: SC Memorial Healthcare International SRL, București · Institutul Regional de Oncologie, Iași · S C Oncocenter Oncologie Clinica S R L, Timișoara
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
HER2-expressing ovarian cancer: two-medicine maintenance compared with bevacizumab alone
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
For: Ovarian Cancer
2 centres: Gral Medical S.R.L, București · Medeuropa SRL, Oradea
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Platinum-resistant ovarian cancer or relapsed lung adenocarcinoma: first-in-human test of TUB-040
The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of three parts: In dose escalation, ovarian cancer participants and lung cancer participants receive increasing doses of TUB-040 until the maximal tolerated dose is found. In dose optimization, at least two doses are compared with each other to determine which dose is optimal for participants. In dose expansion, a single dose will be used in a larger number of participants.
TUB-040 is given IV every 3 weeks until the disease progresses or the participants has to stop due to side effects.
For: Ovarian Cancer, Non-small Cell Lung Cancer
One centre: Arensia Exploratory Medicine, Cluj-Napoca
The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting, with at least one site in Romania. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.
Tell us what we can improve
We use optional technologies to measure usage and campaigns and improve OncoDots. You can accept, decline, or choose separately.
